Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
In cancer inpatient settings, intravenous (IV) opioids are frequently administered in a bolus
fashion in order to obtain immediate pain relief. However, data on the abuse liability (AL)
potential of IV opioids in cancer patients is limited. No study has investigated the effect
of different IV infusion rates on AL potential in patients receiving parenteral opioids for
pain control. This phase IV trial will determine the AL potential of a slow IV hydromorphone
(SH) bolus administration compared with a fast IV hydromorphone (FH) bolus administration
among inpatients with cancer pain. It will also determine the analgesic efficacy and adverse
effect profiles of SH versus FH bolus infusions, and explore the relationship between
pharmacogenetics and pharmacokinetic (PK) and pharmacodynamic (PD) effects of hydromorphone.
This study will eventually help develop evidence-based guidelines regarding the best style of
IV opioid administration which will achieve the most optimal pain control while avoiding the
undesirable complication of nonmedical opioid use